[PTLA] Portola Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 25.06 Change: 6.33 (33.8%)
Ext. hours: 24.85 Change: -0.21 (-0.84%)

chart PTLA

Refresh chart

Strongest Trends Summary For PTLA

PTLA is in the long-term down -65% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company?s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen t

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -2.28% Sales Growth - Q/Q-2.2% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-31.53% ROE-36.59% ROI
Current Ratio9.89 Quick Ratio Long Term Debt/Equity Debt Ratio0.1
Gross Margin Operating Margin-1592.24% Net Profit Margin-1595.01% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities113.04 M Cash From Investing Activities9.44 M Cash From Operating Activities-47.15 M Gross Profit
Net Profit-46.91 M Operating Profit-46.5 M Total Assets486.3 M Total Current Assets403.45 M
Total Current Liabilities40.79 M Total Debt Total Liabilities67.32 M Total Revenue2.36 M
Technical Data
High 52 week37.76 Low 52 week15.46 Last close30.94 Last change1.91%
RSI68.73 Average true range1.39 Beta1.71 Volume8.33 M
Simple moving average 20 days15.82% Simple moving average 50 days15.78% Simple moving average 200 days14.08%
Performance Data
Performance Week24.76% Performance Month18.27% Performance Quart-2.7% Performance Half8.41%
Performance Year-17.97% Performance Year-to-date58.5% Volatility daily3.23% Volatility weekly7.23%
Volatility monthly14.81% Volatility yearly51.32% Relative Volume1513.75% Average Volume1.04 M
New High New Low

News

2020-06-24 10:36:49 | Portola Pharmaceuticals Inc PTLA: Hedge Funds Are Cashing Out

2020-06-17 23:30:10 | Rigrodsky & Long, P.A. Files Class Action Suit Against Portola Pharmaceuticals, Inc.

2020-06-05 17:24:28 | SHAREHOLDER ALERT: WeissLaw LLP Reminds QUMU, TCO, PTLA, and WLTW Shareholders About Its Ongoing Investigations

2020-06-04 10:15:03 | KLXE, TORC, TERP, and PTLA SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

2020-05-28 10:11:00 | Lifshitz Law Firm, P.C. Announces Investigation of Franklin Financial Network, Inc., Mobile Mini, Inc., Portola Pharmaceuticals, Inc., resTORbio, Inc., Stemline Therapeutics, Inc., Taubman Centers, Inc. and Willis Towers Watson Public Limited Company and

2020-05-26 11:00:00 | MERGER ALERT - QES and PTLA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

2020-05-22 13:00:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - MINI, WLTW, PTLA

2020-05-21 14:10:40 | SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, and QES Shareholders About Its Ongoing Investigations

2020-05-19 12:15:00 | IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - TORC, KLXE, PTLA

2020-05-19 10:14:48 | KLXE, FSB, PTLA, and STML SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

2020-05-18 16:02:00 | Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting

2020-05-18 14:00:00 | MERGER ALERT - STML and PTLA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

2020-05-16 15:00:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA

2020-05-15 18:00:00 | SHAREHOLDER ALERT: Monteverde & Associates PC is Investigating the Following Transaction

2020-05-15 16:48:00 | Macy’s and Portola See Investor Activists Buy Up Stakes

2020-05-15 14:39:18 | Lifshitz Law Firm, P.C. Announces Investigation of KLX Energy Services Holdings, Inc. KLXE, Quintana Energy Services, Inc. QES, Portola Pharmaceuticals, Inc. PTLA, and Stemline Therapeutics, Inc. STML

2020-05-15 14:35:00 | MERGER ALERT - TERP, PTLA, and QES: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

2020-05-15 13:20:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm

2020-05-14 17:30:20 | SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, QES, and TERP Shareholders About Its Ongoing Investigations

2020-05-14 08:00:00 | U.S. Centers for Medicare & Medicaid Services CMS Proposes Extending New Technology Add-on Payment NTAP Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year

2020-05-13 12:40:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA

2020-05-12 17:07:43 | Hedge Fund Tells Alexion Management to Sell Company

2020-05-12 09:51:13 | KLXE, PTLA, STML, and TORC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

2020-05-11 15:30:00 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA

2020-05-11 13:40:58 | Lifshitz Law Firm, P.C. Announces Investigation of KLX Energy Services Holdings, Inc. KLXE, Portola Pharmaceuticals, Inc. PTLA, Stemline Therapeutics, Inc. STML and Zuora, Inc. ZUO

2020-05-11 10:05:02 | Portola Pharmaceuticals PTLA Reports Q1 Loss, Misses Revenue Estimates

2020-05-11 08:00:00 | Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

2020-05-09 08:30:00 | SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - TORC, WMGI, PTLA

2020-05-08 12:33:00 | NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: PORTOLA PHARMACEUTICALS, INC. NASDAQ - PTLA, STEMLINE THERAPEUTICS, INC. NASDAQ - STML AND WILLIS TOWERS WATS

2020-05-07 11:40:00 | Shareholder Alert: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA

2020-05-07 10:40:25 | KLXE, PTLA, and STML SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

2020-05-06 13:39:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Portola Pharmaceuticals, Inc. - PTLA

2020-05-06 11:26:03 | Alexion ALXN Beats on Q1 Earnings & Sales, Lowers Guidance

2020-05-06 09:46:01 | Company News for May 6, 2020

2020-05-06 09:45:08 | Is Portola Pharmaceuticals NASDAQ:PTLA Using Debt Sensibly?

2020-05-05 23:35:00 | Shareholder Investigation: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA

2020-05-05 20:02:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Portola Pharmaceuticals, Inc.

2020-05-05 16:02:00 | Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion

2020-05-05 15:10:00 | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc.

2020-05-05 14:23:00 | Moore Kuehn Encourages TORC, STML, KLXE, and PTLA Investors to Contact Law Firm

2020-05-05 13:00:00 | PORTOLA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout

2020-05-05 12:42:00 | Why Portola Pharmaceuticals Is Skyrocketing Today

2020-05-05 12:39:00 | Portola Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Sale Of Portola Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm

2020-05-05 12:30:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Portola Pharmaceuticals, Inc. to Alexion Pharmaceuticals, Inc. is Fair to Shareholders

2020-05-05 11:13:00 | Alexion Will Buy Portola Pharmaceuticals for $1.4B

2020-05-05 10:50:21 | Portola Pharmaceuticals: P/E Ratio Insights

2020-05-05 10:48:00 | Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Portola Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Alexion Pharmaceuticals, Inc.

2020-05-05 10:42:00 | Alexion to Buy Portola for $18 a Share, or $1.41 Billion

2020-05-05 10:42:00 | Alexion Pharma to Buy Portola for $18-Share, or $1.41 Billion

2020-05-05 09:50:01 | Biotech Giant Alexion Swipes Blood Disease-Focused Portola In Buyout